Corbus Pharmaceuticals Touts “Catalyst-Rich” 2026 With CRB-701 and CRB-913 Data Readouts Ahead [Yahoo! Finance]
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Last corbus pharmaceuticals holdings, inc. earnings: 3/12 07:05 am
Check Earnings Report
US:NASDAQ Investor Relations:
corbuspharma.com
Company Research
Source: Yahoo! Finance
its two clinical programs and said FDA discussions for second-line cervical and head-and-neck programs are expected in Q1 2026. Corbus says CRB-701 is differentiated from PADCEV by a proprietary antibody, faster tumor internalization and site-specific DAR=2 "click" conjugation that produces a "hyper-stable" ADC potentially reducing peripheral neuropathy and skin toxicity while causing manageable ocular effects; a more mature safety and efficacy dataset is due in summer 2026. CRB-913 —a peripherally restricted CB1 inverse agonist for obesity—showed early SAD/MAD signals with weight loss in all treated patients (˜3% at two weeks) and low neuropsychiatric events in 112 patients, with three-month multi-dose results expected at the end of summer 2026. Interested in Corbus Pharmaceuticals Holdings, Inc.? Here are five stocks we like better. Corbus Pharmaceuticals stock: An explosive 342% YTD surge Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a “catalyst-rich” 2026 at Oppenheimer'
Show less
Read more
Impact Snapshot
Event Time:
CRBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRBP alerts
High impacting Corbus Pharmaceuticals Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
CRBP
News
- Corbus Pharmaceuticals (NASDAQ:CRBP) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.MarketBeat
- Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference [Yahoo! Finance]Yahoo! Finance
- Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences ConferenceGlobeNewswire
- Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms [Seeking Alpha]Seeking Alpha
- Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]Yahoo! Finance
CRBP
Earnings
- 11/12/25 - Miss
CRBP
Sec Filings
- 3/4/26 - Form 4
- 3/2/26 - Form 144
- 2/25/26 - Form 8-K
- CRBP's page on the SEC website